About laurabbook@gmail.com

This author has not yet filled in any details.
So far laurabbook@gmail.com has created 88 blog entries.
16 October 2020

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

2020-10-16T12:38:36-07:00

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models2020-10-16T12:38:36-07:00
16 October 2020

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer

2020-10-16T12:32:13-07:00

*September 2020* The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer2020-10-16T12:32:13-07:00
16 October 2020

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

2020-10-16T12:27:47-07:00

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC2020-10-16T12:27:47-07:00
Go to Top